Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 1
2011 1
2012 2
2013 2
2015 1
2016 3
2017 2
2018 1
2019 1
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Volociximab in cancer.
Almokadem S, Belani CP. Almokadem S, et al. Expert Opin Biol Ther. 2012 Feb;12(2):251-7. doi: 10.1517/14712598.2012.646985. Epub 2011 Dec 22. Expert Opin Biol Ther. 2012. PMID: 22192080 Review.
Radiation Alone After Surgery: Avoiding Trimodality Therapy.
Teckie S, Almokadem S. Teckie S, et al. Among authors: almokadem s. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1027. doi: 10.1016/j.ijrobp.2022.08.066. Int J Radiat Oncol Biol Phys. 2023. PMID: 36922076 No abstract available.
A patient with complex multiple genomic ALK alterations.
Liu X, Rice SJ, Jamis-Dow CA, Abendroth C, Ali S, Almokadem S, Belani CP. Liu X, et al. Among authors: almokadem s. Thorax. 2016 Apr;71(4):383-5. doi: 10.1136/thoraxjnl-2015-207950. Epub 2016 Feb 2. Thorax. 2016. PMID: 26839360 No abstract available.
Phase I study of veliparib in combination with gemcitabine.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Stoller R, et al. Among authors: almokadem s. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2. Cancer Chemother Pharmacol. 2017. PMID: 28770300 Free PMC article. Clinical Trial.
13 results